27-28 Juillet 2024
\nDenver, USA<\/p>\n
ENYO Pharma soutient la fondation am\u00e9ricaine pour les patients atteints du syndrome d’Alport (Alport Syndrome Foundation, ASF) et participera \u00e0 l’\u00e9v\u00e8nement annuel Alport Connect 2024, organis\u00e9 les 27 et 28 juillet \u00e0 Denver (USA).
\nENYO Pharma rencontrera les patients et leur famille pour leur pr\u00e9senter la prochaine \u00e9tude clinique de Phase 2 “ALPESTRIA-1” avec Vonafexor chez les patients atteints du syndrome d’Alport.<\/p>\n
https:\/\/alportsyndrome.org\/for-patients\/alport-connect\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" 27-28 Juillet 2024 ENYO Pharma soutient la fondation am\u00e9ricaine pour les patients atteints du syndrome d’Alport (Alport Syndrome Foundation, ASF) et participera \u00e0 l’\u00e9v\u00e8nement annuel Alport Connect 2024, organis\u00e9 les 27 et 28 juillet \u00e0 Denver (USA). https:\/\/alportsyndrome.org\/for-patients\/alport-connect\/<\/a><\/p>\n Lire la suite »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-4855","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"27-28 Juillet 2024 Denver, USA ENYO Pharma soutient la fondation am\u00e9ricaine pour les patients atteints du syndrome d’Alport (Alport Syndrome Foundation, ASF) et participera \u00e0 l’\u00e9v\u00e8nement annuel Alport Connect 2024, organis\u00e9 les 27 et 28 juillet \u00e0 Denver (USA). ENYO Pharma rencontrera les patients et leur famille pour leur pr\u00e9senter la prochaine \u00e9tude clinique de…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4855"}],"version-history":[{"count":5,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4855\/revisions"}],"predecessor-version":[{"id":5973,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/4855\/revisions\/5973"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nDenver, USA<\/p>\n
\nENYO Pharma rencontrera les patients et leur famille pour leur pr\u00e9senter la prochaine \u00e9tude clinique de Phase 2 “ALPESTRIA-1” avec Vonafexor chez les patients atteints du syndrome d’Alport.<\/p>\n